

Prevalence of hepatitis B, and C in a tertiary care center in South India

Akilandeswari Alagan RAMASAMY¹, S. GEETHA², J. Janifer JASMINE³

¹Department of Digestive Health and Diseases, Government Kilpauk Medical College, Chennai, India

²Department of Medicine, Government Kilpauk Medical College, Chennai, India

³Department of Research, General Hospital, Chennai, India

ABSTRACT

Aims. To estimate the prevalence of Hepatitis B, and Hepatitis C among the tertiary care population of South India.

Method. For this study, patients who had a positive diagnosis of hepatitis "B" or "C" at first were chosen. The testing for hepatitis B was confirmed by HBsAg (ELIZA). The testing for hepatitis C was confirmed by an HCV antibody test (anti-HCV) (enzyme immunoassay (EIA)). Every positive confirmed test for HBV and HCV patients was selected for this present study. The demographic information, including age and gender, was gathered for additional analysis, and the data was presented as percentages and frequencies. Hepatitis B and C data were compared and displayed as percentages and numbers. The study duration was 13 months from January 2023 to February 2024.

Results. 838 patients were found positive for hepatitis B, and C, among them 612 (73%) were found positive for HBV, and 226 (27%) were found positive for HCV. Among the 612 HBV patients, males 429 (70.1%) were higher than females, and 41-60 years (n=200, 46.65%) age groups were higher than other age groups. Among the 612 HBV patients, females were (n=183, 29.9%), and among them, 21-40 years (n=94, 51.4%) age groups were found higher than other age groups. Among the 226 HCV patients, males 188 (83.2%) were higher than females, and 21-40 years (n=102, 54.3%) age groups were higher than other age groups. Among the 226 HCV patients, females were (n=38, 16.8%), and among them, 41-60 years (n=20, 52.6%) age groups were found higher than other age groups.

Conclusion. Males were more likely than females to be infected and to have a positive diagnosis of hepatitis B and C. In the hepatitis B study, patients between the ages of 41 and 60 tended to be more male, whereas patients between the ages of 21 and 40 (reproductive age) tended to be more female. The distribution of patients in the hepatitis C study was reversed: more male patients were discovered in the age range of 21-40 years, while more female patients were identified in the age range of 41-60 years (reproductive age).

Keywords: prevalence, hepatitis B virus (HBV), hepatitis C virus (HCV)

INTRODUCTION

The Hepadnaviridae family includes the 3.2 kb partly double-stranded DNA virus known as the Hepatitis B virus (HBV). The detection, prevention, and treatment of HBV infection were made possible by Dr. Baruch Blumberg's discovery of the "Australia antigen," which is now known as the hepatitis B viral surface antigen (HBsAg), in the 1960s, [1].

HBsAg was estimated by the World Health Organization (WHO) indicates that about one-third of people have a Hepatitis B Virus (HBV) infection. Over 257 million people worldwide suffer from CHB, and each year, nearly 1 million population die as a result of liver cirrhosis, and hepatocellular carcinoma (HCC), [2]. The authors have estimated an average of 1.59 million people in the US have chronic HBV infection (1.25-2.49 million

Corresponding author:

J. Janifer Jasmine

E-mail: jasminemercy777@gmail.com

Article History:

Received: 10 October 2024

Accepted: 12 December 2024

people), based on epidemiologic surveys and imputation studies [3].

As hepatitis B is on high rise and has no cure, likewise globally, hepatitis C (HCV) is also a health concern disease that affects approximately 71•1 million people, or 1% (95% confidence interval: 0.8-1.1) of the total population, who are chronically infected. The most prevalent ways that HCV is spread are through intravenous drug use, hazardous injection practices used in healthcare settings, and direct blood exposure through blood transfusions. In 2015, there were 33.7 cases of HCV worldwide per 100,000 people (95% confidence interval: 21.3-28.7), and an estimated 175 million new cases of HCV infections were diagnosed. Serological indicators of prior or ongoing HCV infection are present in an estimated 2.3 million HIV-positive individuals. Globally, HCV genotypes 1 (44% of cases), 3 (25% of cases), and 4 (15% of cases) are the most frequently occurring infections. Over 20 to 30 years, between 10–20% of people with chronic HCV infection experience consequences such as cirrhosis, end-stage liver disease, and hepatocellular carcinoma [4].

The highly endemic CHB strain is found in Africa, Asia, and a few Central and Eastern European countries. The majority of infections are contracted during infancy, early childhood, or as an adult, while less than 5% of immunocompetent adults have HBV. Africa, Asia, and several Central and Eastern European regions are home to the extremely endemic CHB strain, [5].

A large number of studies have documented individuals infected with HBV, but very few have presented data on treatment eligibility determination. While around ten percent of the 257 million individuals infected with HBV (26 million) may require immediate medical attention due to cirrhosis, a greater percentage (12–25%) can receive therapy in compliance with alternative protocols [6].

With 9.3% of the 0–4 age group of both genders saw the largest reduction in the Crude Incidence Rate (CIR). Infection rates decreased noticeably more quickly in the younger age group than in the oldest age group (80–84 years). The age group under 20 for both genders had the fastest drop in CIRs. Ages 25-39 years (RR 1.37) and 0–9 years (RR 0.52), respectively, had the highest and lowest incidence risks of AHBV infections. 2.63 times higher than the lowest risk is the highest danger. Especially, for both genders, the age-specific RRs were higher than 1 and were notably different for the age categories of 20–69 years and 20–64 years [7]. Recyclable garbage collectors 278 participated in a study, and among them 50.4% of them were women and 49.6% of them were men. The participants ranged in age from 18 to 70 (median age: 33) [8]. Consequences and co-infection of HBV infection are Hepatitis C (HCV), Hepatitis D (HDV), and HIV viruses [9,10]. In this research study, we will discuss HCV also along with HBV.

Age \leq 45 years and male gender were significant indicators for the occurrence of occult HCV infection (OCI) in research with equal numbers of male and female participants [11]. By 2030, very few nations will have successfully eradicated HCV. Since 80% of high-income nations are not on schedule to accomplish HCV elimination targets by 2030 and 67% are off target by at least 20 years, it is unlikely that these nations will achieve HCV eradication before 2050. Most low- and middle-income nations are still in the very early stages, regrettably, the latter group includes the nations with the highest rates of chronic HCV infections, including Pakistan, Egypt, China, and India [12].

Gender-specific treatment and prevention for patients with HBV-related liver disorders should receive more attention, as there are notable clinical disparities between male and female patients [13]. Males are mostly affected by HCC, with rates two to four times higher than in females. This is still the case for HBV-related HCC. The published research on gender inequality's function as a prognostic indicator as well as a risk factor for HBV-related HCC is examined below [14]. A statistically significant advantage in survival for females with HCC over males was found. but mostly neglected topics [15,16].

Even though the biology of HBV and the disease-related information have been extensively studied, many unknown immunologic and pathogenic, current or upcoming antivirals, elements, and approaches meant to reduce immunopathology or increase immunological responses are still uncertain [17]. As several unclear factors exist for HBV and HCV, the prime strategies can be first proper identification (diagnosis) of patients with HBV, and secondly prevention of the spread to other individuals. As not several studies published discussed age, gender, HBV, and HCV, the best knowledge of the processes governing HBV, and HCV clinical disparities in the age, and gender of patients positively diagnosed for HBV, and HCV will be extremely beneficial for the reduction of potential fatal consequences for HBV, and HCV patients.

Ethical clearance

This study is carried out in the chosen study subjects with the agreement of the ethical committee and under the direction of a guide.

MATERIALS AND METHODS

Methodology

Study setting, design, and duration

This observational study was conducted at Government Kilpauk Medical College & Hospital, Chennai, South India in inpatient and outpatient departments from January 2023 to February 2024.

Initial diagnosis for HBV, and HCV

Patients attending both inpatient departments and outpatient departments were clinically diagnosed as routine tests, and patients with positivity for hepatitis B and C were selected for this study.

HBV, and HCV testing

Hepatitis B

Hepatitis B is a viral infection that targets the liver. It can result in either acute or chronic illness. It is brought on by the Hepatitis B virus (HBV), which is spread by contacting an infected person's blood, semen, or other bodily fluids. This can occur during pregnancy, the early years of life, sexual activity, risky injections, or contact with sharp objects. The testing for hepatitis B was confirmed by HBsAg (ELISA).

During acute or chronic HBV infection, high amounts of the protein HBsAg, which is present on the surface of HBV, can be seen in the serum. A person is contagious if they have HBsAg, with the possible exception within 30 days following a dosage of the Hepatitis B vaccination [18].

Hepatitis C

A viral illness that damages the liver is called hepatitis C. Both acute (short-term) and chronic (long-term) sickness may result from it. It may endanger your life. Contact with contaminated blood can result in the transmission of hepatitis C. The testing for hepatitis C was confirmed by an HCV antibody test (anti-HCV) (enzyme immunoassay (EIA) [19].

Inclusion criteria

- Patients positively diagnosed with hepatitis “B”, and “C” who are willing to provide consent for the study period of 13 months from January 2023 to February 2024 were selected for this present study.
- All ages. (No restriction of ages).
- Only HBV and HCV positively diagnosed patients were selected. (No other clinical factors were considered).

Exclusion criteria

- Patients negative for hepatitis “B”, and “C”, and not willing to give consent were excluded from this study.

Study Participants

838 patients with hepatitis “B”, and “C” positivity fulfilling inclusion criteria were selected to conduct this study.

Study procedure

The patients who were first initially diagnosed positively with hepatitis “B”, and “C” were selected for this

study, and their demographic details such as age and gender were collected for further analysis. This study was conducted for around 13 months.

Data collection, and analysis

The 838 study patients' demographic details such as age, and gender, were observed, and documented as collected data. The collected data were further analyzed with demographic details such as age, and gender, and presented as tabular, and graphical presentations.

Statistical analysis of data

The data analysis was done, and the data were expressed as frequencies and percentages. The data were compared for hepatitis B and C and presented as numbers and percentages.

RESULTS

Among the 838 study patients (n=612), 73% were diagnosed positively with hepatitis B, and 226 (27%) were diagnosed positively with hepatitis C. In the 13-month (from January 2023 to February 2024) selection of study subjects, we found 2 (0.2%) patients were positive for both HBV and HCV and were excluded from this study, this report was done to show that 0.2% of co-infection of both HBV and HCV was found in our present study.

Table 1 describes the salient characteristics of Hepatitis B study patients. Among the 612 hepatitis B patients, males were (n=429, 70.1%), and among them the patients with <20 years were (n=11, 2.6%), 21-40 years were (n=163, 38.0%), 41-60 years were (n=200, 46.65), 61-80 years were (n=53, 12.3%), and >81 years were (n=2, 0.5%). Among the 183 (29.9%) female Hepatitis B patients, among them the patients with <20 years were (n=4, 2.2%), 21-40 years were (n=94, 51.4%), 41-60 years were (n=71, 38.8%), 61-80 years were (n=14, 7.6%), and none were found in the age group of >81 years.

TABLE 1. Gender-Based Salient characteristics of Hepatitis B study patients

Hepatitis B (n=612) (73%)	Categories	(n)	(%)	(n)	(%)
Gender	-----	Males (n=429)	70.1	Females (n=183)	29.9
Age (in years)	<20	11	2.6	4	2.2
	21-40	163	38.0	94	51.4
	41-60	200	46.6	71	38.8
	61-80	53	12.3	14	7.6
	>81	2	0.5	-----	00.0

Table 2 describes the salient characteristics of hepatitis C study patients. Among the 226 hepatitis C patients, males were (n=188, 83.2%), and among them the patients with <20 years were (n=27, 14.4%), 21-40 years were (n=102, 54.3%), 41-60 years were (n=51, 27.1), 61-80 years were (n=8, 4.2%), and, none were found in the age group of >81 years. Among the 38 (16.8%) female hepatitis C patients, among them the patients with <20 years were (n=1, 2.6%), 21-40 years were (n=9, 23.7%), 41-60 years were (n=20, 52.6%), 61-80 years were (n=7, 18.5%), and 1 (100%) patient was found in the age group of >81 years.

TABLE 2. Gender-based Salient characteristics of hepatitis C study patients

Hepatitis C (n=226) (27%)	Categories	(n)	(%)	(n)	(%)
Gender	-----	Males (n=188)	83.2	Females (n=38)	16.8
Age (in years)	<20	27	14.4	1	2.6
	21-40	102	54.3	9	23.7
	41-60	51	27.1	20	52.6
	61-80	8	4.2	7	18.5
	>81	---	00.0	1	2.6

DISCUSSION

This present study reported that the HBV-positive study patient's age distribution and also gender-wise age distribution, and was <20 years were 11 male patients, and 4 female patients, 21-40 years were 163 male patients, and 94 female patients, 41-60 years 200 male patients, and 71 female patients, 61-80 years were 53 male patients, 14 female patients, and 2 male patients was found >81 years. We found that in each age group, the number of male patients was higher than that of female patients with HBV, and it is due to the reason that in India, a high number of male members are wanderers for multiple works mainly involving immoral sexual behaviors. A high number of females will stay at home and do the home-making work (high exposure), this could be the reason for the male patients are in higher numbers than females with HBV. CDC reports some behavioral factors are reasons why male patients were higher with HBV than female patients, that the individuals with a history of several sexual partners or sexually transmitted infections; usage of drugs by infected injections are those who are currently or were previously detained in a jail, prison, or other detention facility; and those who have a history of hepatitis, [20].

Wong et al. retrospectively examined an epidemiological study that showed concomitant medical illnesses between 2004 and 2015 by analyzing a US health-

care claims database that included 121,568 matched controls and 44,026 patients with chronic HBV, and in 2000-2004, the percentage of male patients was 46.9%, which raised to 54.6% in the years of 2014-2017, and they found that co-morbid conditions such as hypertension, diabetes mellitus, cardiovascular diseases, and malignancy. The study also reported the average age of HBV patients increased ($P < 0.001$), from 48.1 to 51.8 years for commercial/Medicare patients and 44.1 to 50.2 years for Medicaid patients [21].

The other published data by Mangowi I et al states the reason for the higher number of males in Tanzania, and Tanzania is one of the LMI countries and their study reports that the male gender was significantly and substantially associated with HBsAg positivity on multivariate analysis (odds ratio: 7.16, 95% CI: 1.81-28.2, $P = 0.005$). The reason for the higher number of males with HBV was household contacts, over half of household contacts were not vaccinated against HBV, and the majority had low knowledge about HBV infection and transmission, [22].

One important factor influencing social outcomes, including health, is gender, and Regitz-Zagrosek V et al report shows that the subject of gender-biased differential response is pertinent in many health fields, such as the prevalence, risk factors, clinical aspects, and treatment of diseases. Research has indicated an increasing interest in gender differences in health. However, more research on the possible involvement of gender differences in the epidemiological pattern of HCV infection in medical practice and research is necessary, [23].

Thus, this present study presented that the HCV-positive study patient's age distribution and also gender-wise age distribution, and was <20 years were 27 male patients, and 1 female patient, 21-40 years were 102 male patients, and 9 female patients, 41-60 years were 51 male patients, and 20 female patients, 61-80 years were 8 male patients, 7 female patients, and 1 female patient was found >81 years. We found that in each age group, the number of male patients was higher than that of female patients with HCV. We cogitate that the higher exposure to an infected environment is the main reason that males are more susceptible to HCV than females.

Qureshi H et describes that aside from blood transfusion emergencies, male predominance can be explained by differences in everyday life circumstances, environmental experiences, and social, cultural, and occupational aspects that men engage in more frequently than women, particularly in marginalized groups and slum areas. These include issues like IV drug use, circumcision, sharing toothbrushes or shaving razors, tattooing, wet cupping (Higama), or illegal sexual intercourse, [24]. Degenhardt L et al. described that the

gender differences in HCV infection rates may reflect variations in risky behavior patterns specific to each gender, [25, 26]. Zhang C et al. reported in their study that male patients (101) were more infected with HCV than female patients (18) (χ^2 -13.343, p-value-<0.01), and the age groups were <20 years were 4, 21-30 years were 47 patients, 31-40 years were 37 patients, 41-50 years were 21, >51 years were 10 patients, not provided why males patients with HCV were higher than females, [27].

In the current study, 2 (0.2%) patients were infected with co-infection of both HBV and HCV, whereas Lu MY et al reported that 4.9% of HBV carriers in endemic HBV infection countries, like Vietnam, also tested positive for anti-HCV antibodies, and among Vietnamese males who have sex with men (MSM), injectable drug use was also associated with HCV infection. Three-quarters had sold sex to more than ten clients in the previous month, and they mostly did it on the street or in other public places. Using a condom for each vaginal or anal sex act is known as consistent condom use, [28].

Deuffic-Burban S et al, and Nienhaus A. et al described the other reason for the higher number of males infected with HBV, and HCV in healthcare units as the healthcare workers Healthcare professionals (HCWs) come into touch with bodily fluids from infected patients. Repeatedly performing exposure-prone procedures (EPPs) that could result in employee injury is a particularly significant concern. One of the most commonly reported occupational hazards in the healthcare industry is injuries to medical and health personnel caused by sharp or pointed objects, [29, 30].

CONCLUSION

The higher number of populations infected, and diagnosed positively for hepatitis, B, and C, were males than females. Among the hepatitis B study patients, a higher number of male patients were found in the age group of 41-60 years, whereas a higher number of female patients were found in the age group of 21-40 years (reproductive age). Among the hepatitis C study patients, it was vice versa, a higher number of male patients were found in the age group of 21-40 years, whereas a higher number of female patients were found in the age group of 41-60 years (reproductive age).

Males are more prone than females to be exposed to HBV, to develop a chronic infection, and to have consequences such as cirrhosis and hepatocellular carcinoma (HCC) reasonably due to high exposures to immoral sexual behaviors, male sexing with males (MSM), consistent condom use, sex in the streets, and public places, and drug by injection with infected syringes, injuries by infected shapes and household contacts with infectious environments. Sexual dimorphism also plays a significant role in HBV infection. Likewise, HCV is also transmissible by exposure to infected shape objects, and as several healthcare workers who handle hospital biowaste are male members, hence male members require special attention in diagnosing for HBV, and HCV.

Conflict of interest: none declared
Financial support: none declared

REFERENCES

- Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B virus infection: overview. *Adv Exp Med Biol*. 2020;1-6. https://doi.org/10.1007/978-981-13-9151-4_1
- WHO. Global hepatitis report. Geneva: World Health Organization, 2017. <https://www.who.int/hepatitis/publications/global-hepatitisreport2017/en/> (accessed Oct 25, 2020)
- Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of chronic hepatitis B virus infection in the United States. *Am J Gastroenterol*. 2020;115(9):1429-38. <http://doi.org/10.14309/ajg.0000000000000651>
- Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. *Clin Res Hepatol Gastroenterol*. 2021;45(3):101596. <https://doi.org/10.1016/j.clinre.2020.101596>
- Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. *Lancet Gastroenter Hepatol*. 2019;4(7):545-58. [https://doi.org/10.1016/S2468-1253\(19\)30119-0](https://doi.org/10.1016/S2468-1253(19)30119-0)
- Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2021;6(2):106-19. [https://doi.org/10.1016/S2468-1253\(20\)30307-1](https://doi.org/10.1016/S2468-1253(20)30307-1)
- Han Y, Li Y, Wang S, Chen J, Zhang J. Temporal trend analysis of acute hepatitis B virus infection in China, 1990–2019. *Epidemiol Infect*. 2024;152:e48. <https://doi.org/10.1017/S095026882400044X>
- dos Santos Weis-Torres SM, Fitts SM, Cardoso WM, Junior MG, Lima LA, Bandeira LM, et al. High level of exposure to hepatitis B virus infection in a vulnerable population of a low endemic area: a challenge for vaccination coverage. *Int J Infect Dis*. 2020;90:46-52. <https://doi.org/10.1016/j.jid.2019.09.029>
- Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, McDonald B, Ong J, Stone J, Easterbrook P, Vickerman P. Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis. *J Viral Hepat*. 2020;27(3):294-315. <https://doi.org/10.1111/jvh.13217>
- Stockdale AJ, Kreuels B, Henrion MY, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. *J Hepatol*. 2020 ;73(3):523-32. <https://doi.org/10.1016/j.jhep.2020.04.008>
- Yosef T, Hussein MM, Elzohary A, George Michael T. Age and Gender are Predictors for Occult Hepatitis C in Egyptian Sustained Responders to Directly Acting Antivirals. *Egypt J Hosp Med*. 2022;89(1):4552-7. <https://doi.org/10.21608/ejhm.2022.258684>
- Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. *World J Hepatol*. 2022;14(1):1. <https://doi.org/10.4254/wjh.v14.i1.1>

13. Liu M, Li L, Zhao J, Ungvari GS, Ng CH, Duan Z, et al. Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China. *PeerJ*. 2022;10:e13828. <https://doi.org/10.7717/peerj.13828>
14. Wu EM, Wong LL, Hernandez BY, Ji JF, Jia W, Kwee SA, Kalathil S. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. *Hepatoma Res*. 2018;4:66. <https://doi.org/10.20517/2394-5079.2018.87>
15. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, et al. Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis. *Cancer*. 2014;120(23):3707-16. <https://doi.org/10.1002/cncr.28912>
16. Farinati F, Sergio A, Giacomini A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? *Eur J Gastroenterol Hepatol*. 2009;21(10):1212-8. <https://doi.org/10.1097/MEG.0b013e32831a86f8>
17. Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. *Nat Rev Immunol*. 2022;22(1):19-32. <https://doi.org/10.1038/s41577-021-00549-4>
18. Navvabi N, Ansari MK, Navvabi A, Chalipa HR, Zitricky F. Comparative assessment of immunochromatography and ELISA diagnostic tests for HBsAg detection in PCR-confirmed HBV infection. *Rev Gastroenterol Mex (Engl Ed)*. 2022;87(2):176-80. <https://doi.org/10.1016/j.rgmexen.2021.11.007>
19. Schillie S. CDC recommendations for hepatitis C screening among adults—United States, 2020. *MMWR. Recommendations and Reports*. 2020;69. https://www.cdc.gov/mmwr/volumes/69/rr/rr6902a1.htm?utm_source=mp-fotoscapes
20. Conners EE. Screening and testing for hepatitis B virus infection: CDC recommendations—United States, 2023. *MMWR. Recommendations and Reports*. 2023;72. <https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm>
21. Wong GL, Wong VW, Yuen BW, Tse YK, Luk HW, Yip TC, et al. An aging population of chronic hepatitis B with increasing comorbidities: a territory-wide study from 2000 to 2017. *Hepatology*. 2020;71(2):444-55. <https://doi.org/10.1002/hep.30833>
22. Mangowi I, Mirambo MM, Kilongo SB, Mlewa M, Nyawale H, Majinge D, et al. Hepatitis B virus infection, associated factors, knowledge and vaccination status among household contacts of hepatitis B index cases in Mwanza, Tanzania. *IJID regions*. 2024;10:168-73. <https://doi.org/10.1016/j.ijregi.2023.12.007>
23. Regitz-Zagrosek V. Sex and gender differences in health: Science & Society Series on Sex and Science. *EMBO Rep*. 2012;13(7):596-603. <https://doi.org/10.1038/embor.2012.87>
24. Qureshi H, Arif A, Riaz K, Alam SE, Ahmed W, Mujeeb SA. Determination of risk factors for hepatitis B and C in male patients suffering from chronic hepatitis. *BMC Res Not*. 2009;2:1-6. <https://doi.org/10.1186/1756-0500-2-212>
25. Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. *Lancet Infect Dis*. 2016;16(12):1385-98. [http://doi.org/10.1016/S1473-3099\(16\)30325-5](http://doi.org/10.1016/S1473-3099(16)30325-5)
26. Le LV, O'Connor S, Tran TH, Maher L, Kaldor J, Sabin K, et al. High hepatitis C virus infection among female sex workers in Viet Nam: strong correlation with HIV and injection drug use. *Western Pac Surveill Response J*. 2019;10(3):9. <https://doi.org/10.5365/wpsar.2019.10.1.002>
27. Zhang C, Ren Q, Chang W. Epidemiological features and risk factors for acquiring hepatitis B, hepatitis C, and syphilis in HIV-infected patients in Shaanxi Province, Northwest China. *Int J Environ Res Public Health*. 2020;17(6):1990. <https://doi.org/10.3390/ijerph17061990>
28. Lu MY, Chen CT, Shih YL, Tsai PC, Hsieh MH, Huang CF, et al. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. *Sci Rep*. 2021;11(1):8554. <https://doi.org/10.1038/s41598-021-87975-5>
29. Deuffic-Burban S, Delarocque-Astagneau E, Abiteboul D, Bouvet E, Yazdanpanah Y. Blood-borne viruses in health care workers: prevention and management. *J Clin Virol*. 2011;52(1):4-10. <https://doi.org/10.1016/j.jcv.2011.05.016>
30. Nienhaus A, Kesavachandran C, Wendeler D, Haamann F, Dulon M. Infectious diseases in healthcare workers—an analysis of the standardised data set of a German compensation board. *J Occup Med Toxicol*. 2012;7:1-7. <https://doi.org/10.1186/1745-6673-7-8>